Now, Erbitux has been approved after all, and ImClone's stock has rebounded.
现在，西妥昔单抗毕竟还是获批了，英克隆的股价也已反弹。
The 222 patients treated with Erbitux and chemotherapy survived for an average of 40 weeks.
接受艾比特思和化学疗法联合治疗的222名患者平均幸存了40周。
Erbitux targets a protein known as epidermal growth factor receptor, or EGFR, to block the signal.
Erbitux定向作用于一种蛋白质表皮生长因素受体或EGFR阻断其信号。
Erbitux, for example, binds to a cell-surface protein called epidermal growth-factor receptor (EGFR).
例如，艾比特思和名为表皮生长因子受体(EGFR)的细胞表面蛋白的结合。
ImClone will keep 39 per cent of US revenues from Erbitux, with Bristol-Myers Squibb taking the rest.
英克隆将提留西妥昔单抗在美收入的39%，而百时美施贵宝将获得其余部分。
The new study aimed to see if addition of the drug cetuximab, also known as Erbitux, would help patients even more.
最新的研究看出如果加用西妥昔单抗(又名爱比妥)可以明显增加这种手术切除的优势。
And ImClone Systems Inc's cancer drug Erbitux carries a warning due to serious and sometimes fatal reactions in about 3 percent of patients.
而英克隆系统公司的抗癌药物Erbitux引起警告是由于百分之三左右的患者中存在严重并且有时甚至致命的反应。
He did, however, combine it with Erbitux, an antibody that binds to and thus disables a protein that promotes the proliferation and growth of cells.
但是，他将其和一种名为艾比特思的抗体联合了起来，后者通过与促进癌细胞扩散和生长的蛋白结合来对它进行抑制。
Because BMS will keep the North American marketing rights for Erbitux, ImClone's blockbuster cancer drug, much of the firm's current revenue will not go to the buyer.
因为百时美施贵宝仍将拥有ImClone公司的抗癌拳头产品Erbitux(爱必妥)北美市场的销售收益，这将使收购方无法获得该公司现有的大部分收益。
A study in Canada showed that as a last-ditch treatment for colorectal cancer, Erbitux lengthened lives by an average of about one and a half months compared with not treating the cancer at all.
加拿大的一项研究表明，作为结肠直肠癌的最后用药，与完全不治疗相比，俄比塔克斯(erbitux)可以延长患者平均一个半月的生命。
A study in Canada showed that as a last-ditch treatment for colorectal cancer, Erbitux lengthened lives by an average of about one and a half months compared with not treating the cancer at all.
加拿大的一项研究表明，作为结肠直肠癌的最后用药，与完全不治疗相比，俄比塔克斯(erbitux)可以延长患者平均一个半月的生命。
应用推荐